Skip to content

Poly-4-Hydroxybutyrate Scaffold in Rhytidectomy

Clinical Use of Poly-4-Hydroxybutyrate Scaffold in Rhytidectomy- A Pilot Study

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07132892
Enrollment
6
Registered
2025-08-20
Start date
2025-12-01
Completion date
2027-12-31
Last updated
2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tissue Adhesion

Brief summary

The study is being conducted to objectively assess tissue changes following the use of P4HB in rhytidectomy to understand how the utilization of the surgical mesh may affect tissue mechanical strength and elasticity, wound healing, and scar formation dynamics.

Detailed description

This is a prospective study designed to follow six (6) qualified and consenting adults, 18-80 years of age scheduled for an elective rhytidectomy with the Principal Investigator (PI). Subjects will be evaluated at baseline, month 1, month 6 and month 12. The effects of the study device will be analyzed at all follow up visits through clinical/3D photography, non-invasive skin assessments and subject/physician questionnaires. The PI will be collecting tissue samples during their surgical procedure, month 6 and month 12 visits. Histopathology will be completed on the collected sample to assess changes of the tissue after the subjects rhytidectomy.

Interventions

DEVICEGalaflex Lite Scaffold

The GalaFLEX LITE is a surgical mesh scaffold composed of poly-4-hydroxybutyrate (P4HB) developed to prolong strength retention and reinforce soft tissue in patients undergoing plastic and reconstructive surgery.

Sponsors

Jeffrey M. Kenkel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Study procedure will be used to assess changes of the tissue.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Eligibility Criteria Inclusion Criteria 1. Healthy adults 18-80 years of age 2. Planned/scheduled rhytidectomy at UT Southwestern with the study doctor 3. Willing to return for follow up visits and undergo study evaluations

Exclusion criteria

1. Individuals diagnosed with known reaction to device material (tetracycline hydrochloride, kanamycin sulfate, etc) 2. Individuals who have significant scarring on the test area 3. Individuals with a disorder to negatively affect wound healing

Design outcomes

Primary

MeasureTime frameDescription
UltrasonographyBaseline, Month 3 and Month 6 and Month 12Ultrasonography will be used to evaluate the skin thickness and density for research purposes.
Bio-mechanical Tissue CharacterizationBaseline, Month 3 and Month 6 and Month 12BTC will be used to measure skins laxity, viscoelasticity deformation, stiffness, energy absorption, elasticity, and deformation values for research purposes. Change from baseline will be calculated to assess change

Secondary

MeasureTime frameDescription
Histological AssessmentBaseline, Month 6 and Month 12Tissue will be obtained, for research purposes, to assess histological evaluation assessment. Change from baseline will be calculated to assess change
Instron Biomedical TestingBaseline, Month 6 and Month 12The Instron device measures the mechanical properties of the tissue.
Face-Q: Satisfaction with Facial AppearanceBaseline, Month 6 and Month 12scale that measures a patient's overall satisfaction with how their face looks. It assesses things like symmetry, harmony, proportion, and vitality. A scale that measures a patient's overall satisfaction with how their face looks. It assesses things like symmetry, harmony, proportion, and vitality. A score from 0 to 100, where a higher score indicates a better outcome or greater satisfaction
Face-Q: Satisfaction with OutcomeBaseline, Month 6 and Month 12A series of positively worded questions to ask patients directly how they feel about the outcome. A score from 0 to 100, where a higher score indicates greater satisfaction with the outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026